



Attorney Docket: 147/50194  
PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: REGINA SCHOEMAKER  
Serial No.: 09/917,858  
Filed: JULY 31, 2001  
Title: USE OF MOXONIDINE FOR POSTMYOCARDIAL  
INFARCTION TREATMENT

PRELIMINARY AMENDMENT

**Box Missing Parts**  
Commissioner for Patents  
Washington, D.C. 20231

Sir:

Preliminary to examination of the above-captioned patent application,  
kindly amend the application as follows:

In the specification:

Please rewrite the paragraph beginning at the third line from the bottom  
of page 7 and continuing through the eighth line from the top of page 8 as  
follows:

The following studies were performed on male Wistar rats  
(270 to 320 g, Harlan Zeist, Netherlands). The rats were kept  
in rooms with a 12 h light/dark cycle and had free access to  
standard rat diet and water. The animals underwent coronary  
artery ligation (MI rats) or sham operation without ligation  
(sham rats). After 24 hours the MI rats were randomized and  
implanted with osmotic minipumps (Alzet, Model 2001) in order  
to administer moxonidine in a dose of 3 or 6 mg/kg-day s.c.  
(subcutaneously) or only operated on without pump implant. The  
moxonidine treatment was continued up to the end of the  
experiment three weeks after the surgical procedure.

Please rewrite, the paragraph appearing at lines 2 through 12 of page 11 as follows:

The data obtained were expressed as group means  $\pm$  SEM (standard error of the mean) unless otherwise stated. Only data of infarcted hearts with an infarct area covering the major portion of the free heart wall of the left ventricle were included in the evaluation since smaller infarct areas are usually fully compensated hemodynamically. The data were analyzed by one-way analysis of variance (ANOVA) followed by post-hoc Bonferroni analysis. Differences in the structural parameters in moxonidine treated and untreated infarcted hearts were determined by Student t-test independently for the two groups.

#### REMARKS

The foregoing amendments are respectfully submitted to present linguistic clarifications in the specification.

If there are any questions regarding this amendment or the application in general, a telephone call to the undersigned would be appreciated since this should expedite the prosecution of the application for all concerned.

Respectfully submitted,

October 25, 2001

  
J. D. Evans

Registration No. 26,269

CROWELL & MORING, LLP  
P.O. Box 14300  
Washington, DC 20044-4300  
Telephone No.: (202) 624-2500  
Facsimile No.: (202) 628-8844

Mark-up of amended paragraphs with deletions in brackets and insertions underlined:

The following studies were performed on male Wistar rats (270 to 320 g, Harlan Zeist, Netherlands). The rats were kept in rooms with a 12 h light/dark cycle and had free access to standard rat diet and water. The animals underwent coronary artery ligation (MI rats) or sham operation without ligation (sham rats). After 24 hours the MI rats were randomized and implanted with osmotic minipumps (Alzet, Model 2001) in order to administer moxonidine in a dose of 3 or 6 mg/kg\_day s.c. (subcutaneously) or only [vehicle] operated on without pump implant. The moxonidine treatment was continued up to the end of the experiment three weeks after the surgical procedure.

The data obtained were expressed as group means  $\pm$  SEM (standard error of the mean) unless otherwise stated. Only data of infarcted hearts with an infarct area covering the major portion of the free heart wall of the left ventricle were included in the evaluation since smaller infarct areas are usually fully compensated hemodynamically. The data were analyzed by one-way analysis of variance (ANOVA) followed by post-hoc Bonferroni analysis. Differences in the structural parameters [of the vessels] in moxonidine treated and untreated infarcted hearts were determined by Student t-test independently for the two groups.